Insurance Co Name

Insurance Co Address

Date

Re: Name: Patient Name

DOB: Enter date of birth

Account #: Enter insurance company account number

To Whom It May Concern:

This letter is to support an appeal for choose a reason Choose an item.Aubagio  
teriflunomide for my patient, Enter patient namefor the management of multiple sclerosis. You have denied coverage for this treatment because insert reason from denial letter here.

Enter patient name has been treated with insert previous therapies used and reasons for discontinuing here.

Choose an item. is medically necessary for my patient because insert rationale here. This is supported by the American Academy of Neurology Practice Guideline recommendation [enter appropriate recommendation here.](https://www.aan.com/Guidelines/home/GetGuidelineContent/900) Additionally, my patient has completed insert screening test and results here, for example Hep B or JCV status.

Aubagio was approved by the U.S. Food and Drug Administration in September 2012 and the first generic versions of Aubagio (teriflunomide) launched in March 2023 as a once –a-day oral tablet for adult patients with relapsing forms of multiple sclerosis. Aubagio (teriflunomide) is a pyrimidine synthesis inhibitor that impedes the function of specific immune cells that have been implicated in MS, and is related to leflunomide, a drug used to treat rheumatoid arthritis.

A randomized trial of teriflunomide (TEMSO) involving 1088 people with relapsing MS showed that teriflunomide reduced relapses compared with placebo over at least 108 weeks. Of two different doses tested (7 mg and 14 mg), the higher dose also slowed progression of disability. Both doses also had a favorable effect on several MRI measures, including a smaller increase in total lesion volume and fewer new and active lesions compared with placebo.1 A second study (TOWER) confirmed the results seen in TEMSO, further supporting the value of this agent for treating relapsing forms of multiple sclerosis.2

[The American Academy of Neurology Practice Guideline: Disease-modifying therapies for Adults with Multiple Sclerosis](https://www.aan.com/Guidelines/home/GetGuidelineContent/900) states that starting therapy with an approved disease modifying therapy is an effective strategy to reduce relapses and MRI activity. Additionally, the guideline describes various reasons for the need to switch therapy, including non-adherence, breakthrough disease (switch to an agent with a different MoA), adverse events, or contraindications to the other available therapies.3

Choose an item. is medically necessary for my patient enter patient name. I respectfully request that you choose consider/reconsider coverage for this patient. Thank you in advance for your timely response.

Sincerely,

Click or tap here to enter text.

Click or tap here to enter text.

Click or tap here to enter text.

1O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. *N Engl J Med*. 2011 Oct 6;365(14):1293-303.

2 Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis(TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurol*. 2014 Mar;13(3):247-56.

3 Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018 Apr 24; 90(17):777-788.